SCHEMBL34461093

SCHEMBL34461093

CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)C(C)C

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KISS1R Q969F8 7/20 0.57
▸ CXCR4 P61073 2/20 0.57
▸ DPP3 Q9NY33 5/20 0.54
▸ C5AR1 P21730 1/20 0.54
▸ NTSR2 O95665 1/20 0.53
▸ NTSR1 P30989 1/20 0.53
▸ SORT1 Q99523 1/20 0.53
▸ IL23R Q5VWK5 1/20 0.53
▸ CAPN1 P07384 2/20 0.51
▸ CTSB P07858 2/20 0.51
▸ OPRD1 P41143 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34461092 0.98 CXCR4 (0.59) KISS1RCXCR4DPP3C5AR1NTSR2
SCHEMBL34461090 0.94 DPP3 (0.59) KISS1RCXCR4DPP3C5AR1IL23R
SCHEMBL34461103 0.92 CXCR4 (0.66) KISS1RCXCR4C5AR1NTSR2NTSR1
SCHEMBL34461114 0.92 DPP3 (0.55) KISS1RCXCR4DPP3C5AR1IL23R
SCHEMBL34461111 0.91 DPP3 (0.56) KISS1RCXCR4DPP3C5AR1NTSR2
SCHEMBL31290071 0.90 CXCR4 (0.61) KISS1RCXCR4DPP3C5AR1NTSR2
SCHEMBL31607206 0.90 CXCR4 (0.61) KISS1RCXCR4DPP3NTSR2NTSR1
SCHEMBL30797894 0.90 KISS1R (0.56) KISS1RCXCR4C5AR1NTSR2NTSR1
SCHEMBL34461095 0.90 CXCR4 (0.68) KISS1RCXCR4C5AR1NTSR2NTSR1
SCHEMBL31620052 0.89 C5AR1 (0.57) KISS1RCXCR4DPP3C5AR1NTSR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS ENDEVICA BIO INC (US) 2026-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS MC1R, MC4R, MC5R KISS1R 154/4885CXCR4 2538/4885DPP3 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback